OB-001 is a highly selective and effective inhibitor of two key efflux pumps (P-gp and BCRP), which are present both on the ...
Company plans to initiate clinical development of tonabersat in 2027, exploring a potential non-invasive treatment option for ...
Closed-loop platform integrates generative AI, biological modelling and automated experiments as XtalPi advances six ...
QIAGEN N.V. announced new artificial intelligence (AI) capabilities to help researchers analyze complex biological and ...
Energenesis Biomedical Co., Ltd. (TWSE: 6657) today announced that it has signed a Memorandum of Understanding ("MOU") with ...
EpiSign Inc. and Geneyx Genomex Ltd. announced a partnership to advance the integration of genomic and epigenomic analysis ...
Figure 1. The 18A queue by month of latest Application Proof, coloured by the modality of each applicant's lead asset. Solid ...
New positioning highlights Aji Bio-Pharma’s specialised CDMO expertise across small molecules, oligonucleotides, peptides, gene therapy, proteins and bioconjugates, backed by Ajinomoto Group’s century ...
Suvoda, a global clinical trial technology company, announced a new release of important advancements since unifying the ...
Lonza, the world's leading contract development and manufacturing organization (CDMO), and Asimov, the company building an AI ...
Abogen Biosciences ("Abogen" or the "Group"), a clinical-stage biotechnology group pioneering RNA innovation, announced that ...
The data establish the first clinical proof-of-mechanism for RNA activation (RNAa) in a human monogenic disease, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results